> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Hansoh commits up to RMB 317m to Hong Kong’s AilsynBio for AI-designed oral cyclic peptides
- URL: https://chinapharmadesk.com/hansoh-ailsynbio-ai-oral-cyclic-peptide-deal/
- Published: 2026-11-13T16:21:55.000Z
- Updated: 2026-11-15T02:53:56.000Z
- Description: Hansoh Pharmaceutical (03692.HK) licensed Hong Kong-based AilsynBio's AI platform on Nov 13 to discover oral cyclic peptides, paying up to RMB 317m ($44.0m) plus royalties and taking program IP.
- Author: Lin Yi
- Tags: Desk brief, Deals & BD, Pipeline

Hansoh Pharmaceutical Group (`HKEX: 03692`) signed a discovery collaboration on November 13, 2026 with Hong Kong-headquartered AilsynBio Limited, licensing AilsynBio’s artificial-intelligence platform to design novel oral cyclic peptide drug candidates across targets selected by Hansoh. Under the [voluntary HKEX filing](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1113/2026111300947.pdf?ref=chinapharmadesk.com) (`03692.HK`, released at 18:30 HKT), wholly owned subsidiary Hansoh (Shanghai) Healthtech Co., Ltd. will acquire intellectual property rights to resulting programs and lead clinical development, while AilsynBio is eligible for up to RMB 317 million (approx. $44.0 million) in aggregate payments plus single-digit royalties on net sales. Neither the upfront cash component nor the number of covered targets was disclosed.

## A priced buyout structure on a day of unpriced AI announcements

Most domestic AI drug-discovery tie-ups on the Hong Kong board omit financial terms altogether. Two hours before Hansoh’s filing hit the exchange, Insilico Medicine (`HKEX: 03696`) [announced a strategic AI discovery pact](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1113/2026111300277.pdf?ref=chinapharmadesk.com) (`03696.HK`, November 13, 2026) with Luoxin Pharmaceuticals covering digestive and metabolic diseases without naming molecule codes, upfront fees, or a milestone ceiling.

Hansoh’s filing puts an explicit cap on its exposure and specifies clean downstream ownership:

- **Target and IP control:** Hansoh holds target-selection rights, takes intellectual property ownership in resulting discovery programs, and controls subsequent preclinical and clinical development.
- **Economics and accounting:** Aggregate payments to AilsynBio are capped at RMB 317 million (approx. $44.0 million), paired with single-digit net-sales royalties, and will be booked directly as Hansoh R&D expenditure. All applicable HKEX Chapter 14 percentage ratios sit below the 5% notifiable-transaction threshold.
- **Capital recycling after Roche:** The deal arrives less than four weeks after Hansoh’s [October 19, 2026 inside-information filing](https://static.cninfo.com.cn/finalpage/2026-10-19/1225610978.PDF?ref=chinapharmadesk.com) (`03692.HK`) licensing ex-Greater China rights on a multi-program antibody-drug conjugate (ADC) portfolio to Roche for $400 million upfront, a $110 million one-year anniversary payment, and more than $15 billion in potential milestones.

## Why Chinese big pharma is buying into oral cyclic peptides

Operating out of Hong Kong Science Park and incubated out of the University of Hong Kong, AilsynBio runs what it calls a “Peptide-Native” dry-wet closed-loop platform ([upgraded on November 5, 2026](https://ailsynbio.com/blog/3?ref=chinapharmadesk.com)) that couples conformational modeling of non-canonical amino acids (NCAAs) with internal high-throughput wet-lab screening. Incorporating NCAAs is central to keeping macrocyclic rings stable against gastrointestinal proteases while preserving membrane permeability—the core engineering bottleneck in turning injectable biologic targets into oral pills.

Global clinical readouts have turned oral cyclic peptides into an active fast-follower race among leading Chinese drugmakers. Johnson & Johnson and Protagonist Therapeutics’ oral IL-23 receptor peptide icotrokinra and Merck & Co.’s oral PCSK9 macrocyclic peptide enlicitide decanoate have validated the modality in late-stage trials, prompting domestic peers such as Haisco Pharmaceutical (`SZSE: 002653`) to [advance oral IL-23 tablet HSK47388 into a 390-patient China Phase 3 psoriasis study](https://chinapharmadesk.com/haisco-hsk47388-oral-il23-phase3/). Rather than licensing a single mid-stage clinical asset, Hansoh—already an active GLP-1 and peptide developer—is locking in platform access to nominate multiple undisclosed targets internally.

Because the collaboration sits at target selection and hit-to-lead discovery, the first externally visible test of the pact will be patent publications or [China CDE](https://chinapharmadesk.com/china-pharma-glossary/) Class 1 IND filings naming Hansoh (Shanghai) Healthtech on cyclic peptide candidates emerging from the program.